Chimeric antigen receptor T-cell therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, Steven T. Rosen

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

Original languageEnglish (US)
Pages (from-to)1093-1106
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Chimeric antigen receptor T-cell therapy'. Together they form a unique fingerprint.

Cite this